Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 1091–1096 | Cite as

The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer

Original Article

Abstract

It has been identified that insulin-like growth factor 1 (IGF-1) activated various pathways of the epithelial-mesenchymal transition (EMT) in a couple of tumors. At the same time, survivin is implicated in EMT of gastric cancer (GC). To date, the impact of survivin on IGF-1-mediated EMT of GC has not been featured. In this work, we used the immunohistochemistry and molecular and cellular experiments to investigate the existence and significance of IGF-1 and survivin. Our findings revealed that survivin protein can be observed in majority of samples in all GC samples. Importantly, survivin expression has an obvious association with GC stage, and metastasis. In vitro, GC cell line BGC823 was treated with different concentrations of IGF-1, resulting in the activation of p-ERK, p-AKT, survivin, and the expression of EMT biomarkers, including N-cadherin, MMP2, and Snail. However, the silencing of survivin eradicated the expression IGF-1-induced EMT biomarkers and affected the migration and invasion of BGC823 cells. In conclusion, IGF-1 signaling activated survivin expression and controlled the expression of EMT biomarkers in the development of GC. This study lays a new stage for the molecular therapy of GC patients in the clinical treatment.

Keywords

IGF-1 Survivin EMT GC 

Notes

Acknowledgments

We are thankful to the other members in our lab for their suggestions.

Conflicts of interest

None

References

  1. 1.
    Li B, Liu HY, Guo SH, et al. The postoperative clinical outcomes and safety of early enteral nutrition in operated gastric cancer patients. J BUON. 2015;20(2):468–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Lyu X, Zheng D, Zhang H, et al. Hyperthermia improves immune function and radiotherapy efficacy in patients with post-operative recurrent gastric cancer. Hepatogastroenterology. 2014;61(136):2428–33.PubMedGoogle Scholar
  3. 3.
    Ryu MH, Yoo C, Kim JG, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51(4):482–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Velho S, Fernandes MS, Leite M, et al. Causes and consequences of microsatellite instability in gastric carcinogenesis. World J Gastroenterol. 2014;20(44):16433–42.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bartucci M, Morelli C, Mauro L, et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 2001;61(18):6747–54.PubMedGoogle Scholar
  6. 6.
    Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res. 2008;10(4):R56.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhang Y, Moerkens M, Ramaiahgari S. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011;13(3):R52.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kang HJ, Yi YW, Kim HJ, et al. BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site. Cell Death Dis. 2012;3, e336.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Li W, Chen YQ, Shen YB, et al. HIF-1α knockdown by miRNA decreases survivin expression and inhibits A549 cell growth in vitro and in vivo. Int J Mol Med. 2013;32(2):271–80.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle. 2009;8(17):2708–10.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lladser A, Sanhueza C, Kiessling R, et al. Is survivin the potential Achilles’ heel of cancer? Adv Cancer Res. 2011;111:1–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Tidball JG, Welc SS. Macrophage-derived IGF-1 Is a potent coordinator of myogenesis and inflammation in regenerating muscle. Mol Ther. 2015;23(7):1134–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Du J, Li B, Fang Y, et al. Overexpression of class III β-tubulin, Sox2, and nuclear survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer. BMC Cancer. 2015;15:536.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Peng Z, Wang CX, Fang EH, et al. Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol. 2014;20(18):5403–10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Katoh M. Epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol. 2005;27(6):1677–83.PubMedGoogle Scholar
  16. 16.
    Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22(3):194–207.CrossRefPubMedGoogle Scholar
  17. 17.
    Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76–84.CrossRefPubMedGoogle Scholar
  18. 18.
    Liao YJ, Fang CC, Yen CH, et al. Niemann-pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: clinicopathological correlations and therapeutical implications. Int J Cancer. 2015;137(6):1341–51.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of General SurgeryAffiliated Hospital of Shandong Academy of Medical SciencesJinanChina
  2. 2.Department of General SurgeryGuanzhuang Hospital of Anqiu CityWeifangChina
  3. 3.Department of General SurgeryHuimin County Hospital of Shandong ProvinceBinzhouChina

Personalised recommendations